Abstract: The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor site of origin. Molecular profiling methodologies have likewise changed such that tests that were performed on patients a few years ago are no longer complete and possibly inaccurate today. As with all rapid change, medical providers can quickly fall behind or struggle to find up-to-date sources to ensure he or she provides optimum care. In this review, the authors provide the current state of the art for molecular profiling/precision medicine, practice standards, and a view into the future ahead. CA Cancer J Clin 2019;69:305-343.
Medicaid Services (CMS), and insurance company attention. Growing acceptance of evidence-based biomarker testing for the purpose of targeting treatment to solid tumors has ensued. Notably, Foundation Medicine's FoundationOne CDx assay, which tests for several well-known markers using next-generation sequencing (discussed later in this review), was recently approved by the FDA and concurrently accepted by the CMS. 1, 2 To facilitate cancer therapy, it is important to distinguish between germline abnormalities and somatic abnormalities. A very good example of this is the recently incorporated BReast CAncer gene (BRCA) germline testing for all patients with pancreatic cancer. Germline testing involves an extensive coverage of BRCA, whereas current somatic testing covers only certain regions of that gene. As mutation analysis evolves into whole exome sequencing, coverage of germline and somatic testing will be similar if not identical. Given the increased need for somatic testing in patients with pancreatic cancer, it is possible that whole exome sequencing will replace germline testing in guidelines to come. As these "standard" tests evolve, they make the choices facing patients and providers more complex while providing hope that harnessing this knowledge will translate into substantial benefits for patients, including cancer cures and prevention.
Molecular Profiling and Its Methodology
Molecular profiling refers to the assessment of DNA, RNA, and/or proteins within an individual patient's cancer using cells obtained from a tumor biopsy or through the capture of tumor cells circulating in the bloodstream, with the latter being less well established as a methodology. The term "molecular profiling" was initially applied to DNA analysis but evolved with advances in technology to take on a broader meaning to encompass analyses of RNA and proteins. DNA-level alterations do not necessarily lead to biological alterations, thus making examination at the "multiomic" (transcriptome and proteome) level imperative. This multipronged analysis results in the generation of an inordinate amount of data that can be processed only with the help of bioinformatic methodology. Bioinformaticians combine a host of scientific and mathematical data to create a computer infrastructure that assists in the analysis and interpretation of biological data and picks out correlations between certain gene mutations and response to a specific therapy. 3 Currently used molecular profiling techniques are as follows:
DNA and RNA • Polymerase chain reaction (PCR) is used to amplify and detect DNA and RNA sequences. Standard PCR involves the amplification of one or more copies of a chosen DNA sequence to produce millions of copies and enable detection and analysis. Reverse transcription PCR converts RNA templates into complementary DNA for molecular analysis.
• In situ hybridization (ISH) localizes and determines a specific DNA or RNA sequence in a tissue section (in situ) or in circulating tumor cells using a labeled complementary DNA, RNA, or modified nucleic acid strand probe. This technique detects gene deletions, amplifications, translocations, and fusions. Gene fusions commonly occur in epithelial cancers as a result of genomic rearrangements or abnormal mRNA processing. ISH techniques include chromogenic ISH and fluorescence in situ hybridization (FISH) . Chromogenic in situ hybridization (CISH) uses brightfield microscopes for label detection. FISH uses fluorescence microscopes for label detection.
• Sanger sequencing examines strands of DNA to identify mutations by analyzing long, contiguous sequencing reads. This DNA sequencing takes place according to the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. This was the primary sequencing method used for well over 20 years and, although it is still widely used, next-generation sequencing (NGS) is now preferred for multigene/variant assessment.
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• NGS is a high-throughput technique that rapidly examines and more broadly detects DNA mutations (often used for circulating tumor DNA), copy number variations (CNVs), and gene fusions (using an RNA sequencing panel) across the genome. NGS can be performed on a range of cancer types using blood, solid tissue, and bone marrow samples. Precise tissue collection and workup are necessary for accurate results. Laboratory regulatory agencies constantly provide updated guidance documents pertaining to the design, development, and use of NGS-based tests, recognizing the importance of NGS in cancer diagnostics and therapeutics.
• Pyrosequencing detects and quantifies mutations, methylation, etc, through sequencing by synthesis-a method that performs DNA sequencing by detecting the nucleotide that is incorporated by DNA polymerase.
• Fragment analysis detects changes in DNA (eg, the length of a specific DNA sequence) or RNA to indicate the presence or absence of an inserted or deleted genomic sequence.
Protein
• Immunohistochemistry (IHC) uses the principles of antibody binding to proteins to determine the levels of protein expression in tissue samples. Tumor-related proteins of interest can include tumor-specific antigens, protein products of oncogenes and tumor suppressor genes, tumor cell proliferation markers, and enzymes.
Molecular Profiling Assays and Why Physician Oncologists and Pathologists Should Be Familiar With Them
Modern approaches to tumor profiling assess DNA, RNA, and proteins to form a detailed molecular map to guide more precise and individualized treatment decisions. Because the field of molecular profiling is continually evolving, physician education is vital. Clinical oncologists and pathologists benefit greatly from an understanding of the technology involved, possibly even gaining hands-on experience in molecular profiling assays and their interpretation. Any treating physician should know what, when, and how to test and how to make subsequent informed, patient-personalized treatment decisions. 4, 5 Correct interpretation of profiling results is critical; many fear that overinterpretation or misinterpretation will lead to treatment of patients with ineffective but expensive therapies, negatively affecting not only patient lives but also the health care budget. Laboratories offering broad molecular profiling services should be suitably Clinical Laboratory Improvement Amendments (CLIA)-certified for this exact purpose to ensure quality control (see CLIA-approved laboratories offering molecular panel analysis, below). However, even CLIA-certified laboratories do not use identical methodologies and techniques, which can still lead to variable results. Reproducibility is key, and the rationale behind assay cutoff limits should be strong. Even before a patient sample is submitted for profiling, the pathologist or the treating physician-whoever plays the lead role in any particular institution-must ensure quality-controlled tissue sample collection. 6, 7 Reputable molecular testing laboratories will advise on the exact set of tumor profiling tests to perform, how to process samples, and how to interpret the final generated report, which is created to inform physicians of treatment choices for their patients. Still, physician education is key to such a critical set of processes.
Biomarker Testing in the Clinic
Targeted therapies are showing efficacy in the right subgroups of patients. Of course, these subgroups must be defined, and this process is becoming more accurate and efficient with evolving molecular testing methods and broader use in research and in the clinic. As this process improves, treatment options will improve for an increasing number of patients while eventually emerging as a more cost-effective, generally beneficial option compared with the currently accepted trial-and-error treatment model. The biomarker information within Tables 1 through 2. 12 is based mainly on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines), NCCN Biomarkers Compendium (NCCN.org, Accessed , and FDA recommendations and approvals (for the full definitions of all genes, please see the Supporting Information). Although the NCCN Biomarkers Compendium details not only predictive but also prognostic, diagnostic, screening, monitoring, and surveillance markers, the focus of this current review is on predictive biomarkers that can be used to guide treatment decisions. Within Tables 1 through  2 .12, the classifications in the "evidence" columns are based on the level of clinical evidence available and the degree of consensus among NCCN panel and other experts. In some cases, clinical evidence comes from large, well-designed, randomized controlled trials, but in many cases, it is mostly based on data from indirect comparisons among randomized trials, phase 2 or nonrandomized trials, multiple smaller trials, retrospective studies, or merely clinical observations. In some cases, substantial clinical data are lacking and evidence comes from clinical experience alone. On the basis of all these factors and how compelling the data are, the evidence is rated as:
1. Based upon high-level evidence, there is uniform NCCN and other expert consensus that the intervention is appropriate (high-level, wide acceptance). 2A. Based upon lower level evidence, there is uniform NCCN and other expert consensus that the intervention is appropriate (lower level, wide acceptance). 2B. Based upon lower level evidence, there is some NCCN and other expert consensus that the intervention is appropriate (lower level, limited acceptance).
Infrequent but Important Site-Agnostic Biomarkers
Microsatellite instability-high tumors and DNA mismatch repair Microsatellite instability (MSI) is the result of inactivation of the DNA mismatch repair (MMR) system and is characterized by a high frequency of frameshift mutations in microsatellite DNA. In a portion of tumors, MSI is caused by germline mutations in one of the MMR genes (MLH1, MSH2, MSH6, or PMS2), which results in hereditary Lynch syndrome. However, the majority (80%) of MSI cases are sporadic, often because of hypermethylation of the MLH1 gene promoter. 8, 9 MSI-high (MSI-H) has been found in as many as 24 primary cancer types, most of which are displayed in Table 3 , 10 ,11 and appears to be a generalized cancer phenotype in about 4% of all adult cancers. Tumor MSI-H status is prognostic (patients with early-stage cancers that are MSI-H have a better prognosis than those with microsatellite stable tumors) as well as predictive-many MSI-H tumors are exquisitely sensitive to PD-1/PD-L1 inhibitors. 12, 13 At present, the FDA has granted approval for practitioners to administer the PD-1 inhibitor pembrolizumab for the treatment of patients with unresectable or metastatic, MSI-H or MMR-deficient (dMMR) solid tumors (site-agnostic). Currently, the approval is for patients with tumors that have progressed after prior treatment who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer (CRC) after progression on a fluoropyrimidine, oxaliplatin, and irinotecan, and in the first line for non-small cell lung cancer (NSCLC). 14, 15 In 2017, the FDA granted accelerated approval of single-agent nivolumab, another PD-1 inhibitor, for the treatment of adult and pediatric patients older than 12 years with MSI-H or dMMR CRC. Subsequently, in 2018, the FDA granted accelerated approval to a combination of nivolumab plus ipilimumab (a CTLA-4 inhibitor) for treatment of the same set of patients. 16, 17 See Table 1 for MSI/MMR biomarker testing recommendations.
Neurotrophic receptor tyrosine kinase
Members of the neurotrophic receptor tyrosine kinase (NTRK) fusion oncogene family, NTRK1/NTRK2/ NTRK3, are most prevalent in rare adult cancer types and in several pediatric cancers, although they can occur in a very small proportion (approximately 1%) of commonly occurring cancer types in adults, including NSCLCs, CRCs, head and neck cancers, thyroid cancers, bladder cancers, gliomas, and malignant melanomas (Table 4   18 ). NTRK1, NTRK2, and NTRK3 fusions and the proteins they encode (neurotrophin receptor kinase A [TRKA], TRKB, and TRKC, respectively) are observed at an increased frequency in highly aggressive cancers such as glioblastoma multiforme, and recognition of their potential oncogenic activity led to the use of this fusion family as a predictive biomarker as well as a drug target. 25 Larotrectinib is an oral and highly selective TRK inhibitor that was granted accelerated approval by the FDA on November 26, 2018, for the treatment of adult and pediatric patients with metastatic or unresectable solid tumors that have an NTRK fusion without a known acquired resistance mutation (NTRK kinase domain mutations, including solvent front mutations). Patients must have a cancer that has progressed after treatment and/or have no satisfactory alternative treatment for their disease. 26 The approval of larotrectinib is the second tissueagnostic FDA approval, after pembrolizumab, for the treatment of cancer. Another TRK inhibitor named entrectinib (RXDX-101) was granted a breakthrough therapy designation by the FDA in 2017, although it has not yet been approved for use as a treatment for adult and pediatric patients who have NTRK-positive, locally advanced or metastatic solid tumors that have either progressed after prior therapies or have no acceptable standard therapy options.
27,28
NTRK fusion testing has evolved massively over the last year or 2, and new discoveries are constantly being made using a range of different assays. The NTRK fusions displayed in Table 4 18 are taken from a study that was originally published in 2018. Although comprehensive at the time, this table does not contain the complete list of fusions known today, in 2019. IHC has been used as an initial screening tool to inform highly sensitive but less available and more expensive molecular testing methodologies. [29] [30] [31] However, it is now clear that IHC does not have sufficient sensitivity to detect all existing NTRK fusion-encoded proteins, meaning that tumor samples should certainly be assayed using FISH or NGS from the get-go. 18 In conclusion, clinicians need to be aware of all 3 TRK targets and arrange adequate testing for all of them.
Germline alterations and their testing
Gene mutations can be somatic or germline; the former spontaneously occur after birth, and the latter are inherited (ie, present at birth). Tumor genetic (somatic) testing detects mutations that may actually be germline alterations, but germline alterations require confirmation in matched normal samples (eg, DNA extracted from white blood cells, buccal swabs, or cultured skin fibroblasts) from the tumorbearing host. Suspected germline mutations and genetic testing are relevant to cancer treatment and prevention.
There is potential for patients to develop tumors at other 35 Finding BRCA1/BRCA2 mutations in the tumor may aid in choosing therapy but requires germline testing for confirmation and consideration of genetic counseling for the family. It has generally been considered that germline testing is not always needed if somatic tumor testing has been done. However, it must be kept in mind that molecular genetic tumor testing can miss a small percentage of inherited cases, where mutations are outside the hotspots covered in the somatic panel or large-scale deletions and duplications have occurred. Conversely, larger gene panel profiling may actually identify previously unknown, clinically relevant alterations that are germline, either de novo or inherited from parents, despite a lack of associated clinical history. 36 In conclusion, taking into consideration the increasing availability of germline testing and whole exome sequencing to identify inheritable mutations, as well as the personal and family history of cancer and the potential need for genetic counseling, medical teams can help provide better treatment selection for patients with some types of cancer and help to create a systematic approach to hereditary risk.
Disease-Specific Biomarkers
In the subsections below and in Tables 2.1 through 2.12, we address the currently accepted genes or gene products that act as predictive biomarkers (and risk assessment markers in some cases) for each specific solid tumor. Details on when in the disease course the presence or levels of these markers should be assessed are also included. Under each of the following subsections, we also include some description of pertinent biomarkers in research. Compelling evidence suggests that these biomarkers will be listed in the NCCN "recommended" biomarker category in the foreseeable future.
Lung cancers
Lung cancer therapy continues to follow the genomic testing paradigm (see Table 2 .1 15, [19] [20] [21] [22] [23] [24] ). All patients with NSCLC should be tested for EGFR, ALK, ROS1, BRAF, and PD-L1 at baseline before treatment. Patients with uncommon mutations of EGFR may also be treated with tyrosine kinase inhibitor therapy. Other recommended markers of interest include EGFR insertion 20 mutations, RET rearrangements, and MET exon 14 mutations. All of these targets are still being actively investigated in clinical studies and hold potential for patient treatment.
Gastrointestinal cancers
Colon and rectal cancers. Oncologists now recommend the assessment of several predictive markers in patients with CRCs (see Table 2 .2). The ideal time to perform genomic testing for treatment purposes is a matter of some controversy and varies depending on disease stage. At the time of initial diagnosis of a stage I, II, or III tumor, it is reasonable to perform MSI testing. Patients with MSI-H, locally confined tumors have a better prognosis, and recommendations are for patients with MSI-H stage II tumors to forgo adjuvant therapy. 37, 38 Additional evidence suggests that 5-fluorouracil (5-FU) and related agents, such as capecitabine, can actually worsen outcomes when delivered as single agents to patients with early-stage MSI-H CRCs. 39, 40 
Genitourinary cancers
Bladder cancers. In The Cancer Genome Atlas extended 2017 study carried out by Robertson et al, findings from the complete cohort of 412 muscle-invasive bladder cancer cases revealed that mutations in the DNA repair genes ATM (n = 57; 14%) and ERCC2 (n = 40; 10%), and deletions in RAD51B (n = 10; 2%) were significant. 55 It was found that all nonsilent somatic ERCC2 mutations were missense, and many could be mapped within the conserved helicase domain. Dominant negative effects on ERCC2 function were observed. 56 Thus, bladder cancer missense mutations in ERCC2 were associated with improved response to cisplatin-based chemotherapy. However, ERCC2 mutations are distributed across the gene, and the functional impact of most individual ERCC2 mutations is unknown. Recently, Li et al reported developing a microscopy-based assay that measures the nucleotide excision repair function of clinically observed ERCC2 mutations. Most helicase domain mutations impaired the function. In addition, a preclinical ERCC2-deficient bladder cancer model showed that ERCC2 loss was sufficient to drive cisplatin sensitivity. Thus, ERCC2 was concluded to be a predictive biomarker in bladder cancer. Moreover, this study underscores the importance of combining genomic and functional approaches in a co-clinical trial to guide precision oncology for conventional chemotherapy agents. Current evidence presented here supports the idea that ERCC2 and ATM are potentially useful markers in muscle-invasive bladder cancer. [55] [56] [57] Prostate cancers. It was recently reported that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring germline mutations in BRCA1/BRCA2 and ATM have superior clinical outcomes after first-line treatment with abiraterone and enzalutamide (see Table 2 .5). 58 The 
Gynecologic cancers Endometrial cancers.
As noted above (see Microsatellite instability high tumors and DNA mismatch repair), the presence or absence of MSI should be determined through universal tumor molecular testing in every patient with uterine cancer (see Table 2 .6). 62 Approximately 2% to 5%
of uterine cancers are because of Lynch syndrome, caused by germline mutations in MLH1, MSH2, MSH6, or PMS2. Abnormalities in MLH1 should prompt hypermethylation testing, as this can also cause tumors to be MSI-H in the absence of a germline mutation. The detection of a germline mutation affects subsequent screening for colon and ovarian cancer and prompts cascade testing to identify other affected family members. The presence of MSI-H because of either a germline mutation or hypermethylation provides an indication for pembrolizumab in the setting of recurrent uterine cancer, based on site-agnostic FDA approval granted in 2017. 13 Phase 2 data demonstrate activity of mTOR inhibitors in endometrioid carcinoma of the uterus, but these trials were not assay-directed to determine whether molecular testing can select for potential activity. 64 Ovarian cancers. The presence of pathogenic mutations in BRCA-related genes identify an important subset of highgrade serous epithelial ovarian cancers that have a specific biology, natural history, and susceptibility to platinum and PARP inhibitors. 63 showed that germline BRCA2 and ATM mutations distinguish lethal from indolent prostate cancers and are associated with shorter survival times and earlier age at death. Antonarakis et al 58 reported that patients with metastatic, castration-resistant prostate cancer harboring germline mutations in BRCA1/BRCA2 and ATM have superior clinical outcomes after first-line treatment with abiraterone and enzalutamide. In the recurrent setting, PARP inhibitors (olaparib and rucaparib) as monotherapy were first approved for ovarian cancer patients with BRCA1/BRCA2 mutations or HRD. This indication has now been expanded to include olaparib, rucaparib, and niraparib as switch maintenance therapy for patients with platinum-sensitive ovarian cancer who have responded to platinum in the second-line or third-line setting. [65] [66] [67] 71 The identification of BRCA-related gene mutations is also necessary to perform cascade testing on family members to identify affected family members who may be candidates for risk-reducing surgery and surveillance to prevent subsequent ovarian, tubal, peritoneal, and breast cancer.
Evaluation of PD-1 and PD-L1 status is useful in patients with ovarian cancer because pembrolizumab is approved for patients with MSI-H tumors based on a site-agnostic label. Single-agent activity for PD-1 inhibitors has been limited in patients with ovarian cancer, but checkpoint inhibitors are under study in the JAVELIN trials. The combination of PARP inhibitors with checkpoint inhibitors has been investigated, and initial response rates of 25% to 30% have been noted. The larger ATHENA trial (A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy; Clini calTr ials.gov identifier NCT03522246) of maintenance rucaparib and nivolumab therapy is currently accruing patients with ovarian cancer who have responded to front-line, platinum-based chemotherapy.
Although initial trial results using MEK inhibitors in the treatment of patients with low-grade serous carcinomas have been disappointing, multiple studies are ongoing investigating MEK inhibitor monotherapy and combination therapy. Other rare ovarian cancers have different molecular profiles, but targeted therapies remain largely unstudied.
Cervical cancers. The treatment of patients with recurrent cervical cancer has been problematic, and their prognosis is dismal. Bevacizumab was approved for recurrent disease in combination with platinums, taxanes, and topotecan; however, no molecular markers have yet been found that can predict patient treatment response. Pembrolizumab was FDA-approved in 2018 for patients with recurrent and metastatic cervical cancer who had disease progression on or after chemotherapy and whose tumors expressed PD-L1, based on a 14% objective response rate seen in KEYNOTE 158 (Study of Pembrolizumab in Participants With Advanced Solid Tumors; Clini calTr ials.gov identifier NCT02628067). Promising data also exist for single-agent nivolumab, which demonstrates a 26% response rate in the recurrent setting (Clini calTr ials.gov identifier NCT02488759). Trials evaluating combination therapy with nivolumab and ipilimumab are currently underway.
Breast cancers
The well-established biomarkers that drive treatment decisions for patients with breast cancers are estrogen receptor (ER) expression, progesterone receptor (PR) expression, and human epidermal growth factor receptor-2 (HER2) overexpression or amplification in the tumor (see Table 2 .8). Determination of ER, PR, and HER2 status is recommended for all newly diagnosed invasive breast cancers and for any recurrences when feasible. These are routinely used to predict response to therapy and guide treatment planning for patients with breast cancer.
Some new markers that show promise for future use in breast cancer are the androgen receptor (AR), ESR1, and PD-L1. Overexpression of AR occurs in a subset of triplenegative breast cancers (TNBC). 72 Clinical trials of ARtargeted treatments have shown promising preliminary results in patients with metastatic, AR-positive TNBC. 73 Mutations in ESR1 occur in the ligand-binding domain of the ER and can lead to a ligand-independent, constitutively active form of the ER. This is a potential mechanism of resistance to aromatase inhibitors. De novo ESR1 mutations have been most commonly detected during or after treatment with aromatase inhibitors for hormone receptor-positive breast cancer. 74 The treatment implication is to consider using selective ER downregulators that target ER directly in the setting of an ESR1 mutation. The role of PD-L1 as a predictive biomarker for the treatment of patients with breast cancer using checkpoint inhibitors will be further delineated with several maturing trials evaluating immune checkpoint blockade in the treatment of breast cancer. In addition, multiparameter genomic assays, such as Oncotype DX ( Central nervous system cancers Although broad panels are often appropriate and especially meaningful in the metastatic setting when conventional therapy has failed, more limited panels may be a consideration (see Table 2 .9 75, 76 ). This can be exemplified by central nervous system tumors, in which genetic alterations are not just prognostic or predictive, but diagnostic. Before 2016, the World Health Organization (WHO) classification relied strictly on histologic features to differentiate tumors of astrocytic and oligodendroglial lineage. 77 Although patients have significantly different treatment paradigms and survival depending on which of these tumor lineages they harbor, 78 occasionally features from both lineages can be found within the same tumor, resulting in a diagnosis of a "hybrid" oligoastrocytoma. This is further compounded by high interobserver discordance; thus, some institutions diagnose this entity more frequently than others. 79 By combining both genotype and classical histologic findings, it is now possible to diagnose nearly all of these tumors to be compatible with either oligodendroglioma or astrocytoma.
This has resulted in modifications to the WHO classification in 2016 to include both histologic phenotype and molecular genotype with consideration of IDH mutation, 1p19q codeletion, ATRX loss, and TP53 mutation when diagnosing gliomas. 75 Furthermore, epigenetic silencing of the promoter of the methyl-guanine methyl transferase gene MGMT by gene promoter methylation is frequently tested because it is highly prognostic and also predictive, correlating with a response to or benefit of alkylating agent chemotherapy. 76 It has been found that most glioblastomas have potential actionable genomic alterations. 80, 81 A recent NGS analysis using a 315-gene panel found that, of 43 patients, 95% had at least 1 therapeutically actionable genomic alteration of a median of 4.5 genomic alterations per patient. The most common genomic alteration detected was in EGFR (40%). Genotype-directed treatments were prescribed in 13 patients, representing a 30% treatment decision impact. Treatment with targeted agents-including everolimus as a single agent and in combination with erlotinib, 
afatinib, palbociclib, trametinib, and BGJ398-elicited no response. 82 A fusion between Brevican (BCAN) and NTRK1 is a potent oncogenic driver of high-grade gliomas and confers sensitivity to entrectinib. 83 A case report of a BCAN-NTRK1 fusion in glioneuronal tumors highlights its clinical importance as a novel, targetable alteration, 84 and an open-label, multicenter, global phase 2 basket study of entrectinib for the treatment of patients with locally advanced or metastatic solid tumors that harbor NTRK1/NTRK2/NTRK3, ROS1, or ALK rearrangements (Clini calTr ials.gov identifier NCT02568267) is currently recruiting glioma patients. For pediatric low-grade gliomas, BRAF V600E is a potentially highly targetable tumor mutation, which was detected in 17% of patients who exhibited poor outcome on receipt of chemotherapy treatment. 85 In a recent evaluation of dabrafenib in a phase 1/2 trial that included 32 children with relapsed or refractory, low-grade gliomas, findings of an objective response rate of 38% and stable disease in another 44% of patients are extremely exciting. It is encouraging that these drugs could be effective agents that allow us to replace chemotherapy entirely for pediatric glioma. 86 Other central nervous system types for which molecular profiling has a role include ependymoma (RELA fusion), diffuse midline cerebellar gliomas (histone 3 mutations), medulloblastoma (WNT vs SHH activated), and ependymoma (C19MC amplification). Although many of these tumors inevitably recur and a broader panel may be useful at some point in the course of the disease to define clinical trial options, obtaining a limited panel that contains the molecular alterations considered within the WHO criteria remains a reasonable option.
We certainly see the potential implication of molecular profiling for a routine part of therapeutic decision making beyond classification and prognostic prediction for patients with glioma. Of other mutations tested, the epidermal growth factor gene EGFR variant vIII encodes a promising molecular target. EGFR amplification could be useful in the treatment of glioblastomas. However, agents targeting EGFR signaling pathways have displayed limited or no therapeutic efficacy in glioblastoma clinical trials. ABT-414 (an investigational, anti-EGFR monoclonal antibody drug conjugate) alone 87 or in combination with temozolomide showed a trend toward improved survival and was safely administered with radiation therapy. 88, 89 The BRAF V600E mutation, which is analyzed using NGS, is predictive and prognostic for low-grade pediatric glioma. This mutation is frequently found in gangliogliomas and in about two-thirds of grade II xanthroastrocytomas. It is assumed that this alteration constitutively activates the RAS/RAK/MEK/ERK kinase pathway. When BRAF kinase inhibitor treatment effects are validated within lowgrade glioma, the drug could transform the BRAF V600E Head and neck cancers PD-1 is highly expressed in head and neck squamous cell carcinomas (HNSCCs) and, in 2016, the PD-1 inhibitors nivolumab 91 and pembrolizumab 92 were both approved for the treatment of HNSCC that has metastasized or recurred on or after treatment with platinum chemotherapy (see Table 2 .11). PD-L1 testing is now recommended in patients undergoing workup for metastatic HNSCC, with the intention of offering pembrolizumab as a treatment option to those with PD-L1-positive tumors.
EGFR is reportedly overexpressed in between 90% and 100% of HNSCCs. 93 
Melanomas
To date, the only FDA-approved predictive biomarker in patients with advanced melanoma is BRAF genotyping (see Table 2 .12). Approximately one-half of melanomas that originate from cutaneous primary sites will harbor a BRAF V600 mutation. 98 This leads to constitutive activation of the MAPK pathway and increased cell proliferation, metastasis, and survival mechanisms. Vemurafenib, dabrafenib, and encorafenib are BRAF-targeted therapies that preferentially inhibit cells harboring the BRAF V600 mutation. It is important to be aware that selective These tests are not strictly specified in the National Comprehensive Cancer Network guidelines but are widely accepted among the sarcoma community. However, patients with low or negative biomarkers can still benefit from immune checkpoint therapies, and some studies have shown marginal differences between groups. The PD-L1 IHC analyses from the Checkmate 067 study demonstrate this concept well: response rates were 43% and 58% with nivolumab monotherapy in patients whose tumors had <5% PD-L1 staining versus >5% PD-L1 staining, respectively. 111 Biomarkers may be useful in the application of nivolumab/ipilimumab combination therapy over nivolumab monotherapy for patients with melanoma based on Checkmate 067 study data. Improvement in PFS with the combination approach was best seen in patients whose tumors harbored a BRAF V600 mutation or had <1% PD-L1 staining (hazard ratios, 0.62 and 0.68, respectively).
The Gray Area Between Research and Clinical Practice
Core clinical markers in current use by expert molecular profiling laboratories, the frequencies of these markers in a range of tumor lineages, and assay types used for their assessment can be found in Table 6 (Caris Molecular Intelligence). Many of the markers and their assays in Table 6 are essentially still classified as belonging in a "research" category, and the NCCN has not yet recommended universal testing for these genes. Nevertheless, they have been reported as actionable and useful by a general consensus of experts in the research community. Because the use of broader gene panels and full-scale NGS is still in the gray area between research and clinical practice, it comes burdened with benefit-to-cost ratio controversies. The field is also evolving rapidly, with fluidity existing in the classification of genes as clearly, possibly, or unlikely to be relevant to treatment considerations. Until recently, approved genetic testing involved a small group of genetic tests carried out in patients with specific cancers for a specific therapeutic purpose. Firmly established examples of mutational status being key to treatment recommendations include pan-RAS testing (KRAS, NRAS, and HRAS) in patients with CRC to direct the use of anti-EGFR therapies cetuximab and panitumumab 45 and HER2 testing in patients with breast cancer to direct the use of anti-HER2-targeted therapies, such as trastuzumab, 112 and tyrosine kinase inhibitor therapies, such as lapatinib. It took many years and a large number of trials involving many patients before pan-RAS and HER2 testing became a standard treatment-predictive approach. Other examples of molecular testing used in standard clinical practice are detailed above (see Disease-Specific Biomarkers). However, as genetic testing evolved into whole genome sequencing, advances in computer technology allowed small-capacity assays to evolve into automated, high-throughput assays with large-scale data collection, classification, storage, and analysis. Thus, real-time, broad gene panel testing combined with relevant patient clinical data are now providing an unprecedented wealth of information. However, the interpretation of the meaning of results is limited by the finding that relatively small pools of evidence are available to validate most markers and their paired targeted therapies. Larger studies and collaborative efforts are certainly needed to further and more widely validate these broader panel markers and gene expression profiles and to integrate them and their targeted therapies into clinical practice (see Absence of Randomized, Controlled Clinical Trials, below). The immediate goal of testing is to translate genetic findings into potentially effective therapy decisions for today's patients. Meanwhile, numerous proof-of-principle trials currently are in progress or in development. One key to accelerating the application of this knowledge is real-time national and international partnerships between cancer researchers and pharmaceutical companies to perform broad-panel profiling and elucidate targeted patient therapies. Concurrently, data pooling is mandatory using universal data-sharing capabilities to maximize the utility of these findings and generate large pools of evidence (see Data Sharing, below). Successes and failures alike will provide a more complete picture, and the result will take us steps closer to effective cancer treatmentand cures. This model is already in practice in the form of basket trials.
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Oncology Basket Trials and Precision Medicine
Current oncology basket trials test therapies across a range of populations using biomarker-driven designs. Such trials choose biomarkers, which must have a clinically feasible assay, to attempt to enrich responses to a particular targeted therapy. The gathering of efficacy data across a range of populations translates to only one primary outcome endpoint, which simplifies the situation while increasing deductive power. These large-scale and small-scale, broad-panel molecular profiling trials include the National Cancer Institute's Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the American Society of Clinical Oncology (ASCO) Targeted Agent and Profiling Utilization Registry (TAPUR) study, and the European Organization for Research and Treatment of Cancer-Screening Patients for Efficient Clinical Trial Access (EORTC-SPECTA) program. These studies attempt to expand the boundaries of precision medicine and build evidence supporting the use of molecularly tailored therapy.
National Cancer Institute's Molecular Analysis for Therapy Choice Trial
The novel, phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice 114 ) trial was initiated in August 2015 and is bringing public and private sectors together to enable access of physician researchers to investigational agents (in addition to approved agents) in an attempt to build the much soughtafter evidence supporting the effectiveness of matching The frequency data presented here are in general consensus with previous studies, although they represent a much broader overview of frequency and types of NTRK fusions than these other studies due to the large volume of tumors studied (more than 11,000 patients were screened). Data from: Gatalica Z, Xiu J, Swensen J, Vranic S. targeted therapy to patient molecular profiles. The primary aim of the NCI-MATCH study is to evaluate the proportion of patients with objective responses (ORs) to targeted therapies predicted to be mechanistically effective based on individual tumor genomic profiling. If the response rate to any mutation-matched therapy is at least 25%, this match will be tested in larger phase 2 trials. There are well over a thousand study locations across the United States, and pharmaceutical and biotechnology companies are providing targeted agents to enrolled patients across these sites. Patients are treated according to their profile (Table 7) and regardless of tissue origin or cancer type. New drugs of interest can be added to the "master" trial at any time. The trial is running under Clini calTr ials.gov identifier NCT02465060, where up-to-date information can be obtained.
Targeted Agent and Profiling Utilization Registry
The TAPUR study is an ongoing, nonrandomized, multicenter clinical trial that opened in 2016. 115 This trial is testing the use of drugs already approved by the FDA that target a specific tumor mutation in individuals with advanced cancer outside of the drug's approved indication. Patients with a range of solid tumors as well as lymphomas and multiple myelomas are eligible for enrollment. As with NCI-MATCH, treatment assignment in this study is based on an existing tumor mutation and not the organ from which the cancer originated. The study aim is to observe the real-world use of targeted therapies in any patient whose tumor tests positive for a selected genomic alteration that is known to be a drug target or has been shown to predict sensitivity to a drug available in this study. The primary outcome measure is the objective response rate (defined as the percentage of participants in a cohort with a complete or partial response at 8 weeks postbaseline or with stable disease at 16 weeks or later postbaseline according to RECIST (Response Evaluation Criteria in Solid Tumors) (for solid tumors), international uniform response criteria (for multiple myeloma), 116 and Lugano criteria (for non-Hodgkin lymphoma).
117,118 Table 7 details the genomic alterations (biomarkers) and targeted therapies of interest at the time of submission of this article for publication, although markers and therapies are continually being refined as the study progresses. It is currently anticipated that TAPUR will enroll over 2500 patients in total. The trial is running under Clini calTr ials.gov identifier NCT02693535, where up-todate information can be obtained.
European Organization for Research and Treatment of Cancer-Screening Patients for Efficient Clinical Trial Access
EORTC-SPECTA is a collaborative European molecular screening program that coordinates several diseasespecific platforms with the aim of identifying actionable mutations and offering specific targeted therapy to patients (Clini calTr ials.gov identifier NCT02834884). 119, 120 This is a large-scale basket trial that operates through one entry point that provides access to multiple studies and to highquality, annotated material for research purposes and provides longitudinal follow-up of patients to understand progression patterns. 121 
Targets of Special Interest: Emerging and in Current Practice
There are several novel biomarkers of great interest, many of which have found a niche in common practice but are continuing to reveal exciting connections and uses. We expand on several these markers below.
Immune Markers and Immunotherapy
Programmed death-ligand 1 expression
The immune checkpoint PD-1/PD-L1 axis is a welldescribed inhibitory pathway that leads to T-cell exhaustion in the tumor microenvironment. 122 Typically, PD-1 on tumor-infiltrating cytotoxic T cells interacts with PD-L1 on tumor cells, causing dampening of antitumor immunity (an adaptive immune response). 123 Tumor types known to be immunogenic typically have relatively high rates of PD-L1 positivity. 124 However, although greater clinical activity of anti-PD-1 agents (nivolumab and pembrolizumab) and PD-L1 agents (avelumab, atezolizumab, and durvalumab) has been consistently observed in patients with PD-L1-positive disease, 125, 126 some clinical trials have found that patients with low PD-L1-expressing tumors can derive significant benefit from anti-PD-1/PD-L1 agents. Therefore, PD-L1 IHC score alone is insufficient for patient selection in many tumor types. Assays have been developed to test for PD-L1 expression, including the PD-L1 IHC assay with 28-8 Dako (developed for nivolumab), 22C3 Dako (developed for pembrolizumab), SP142 Ventana (atezolizumab), SP263 Ventana (durvalumab), and 73-10 Dako (avelumab). These assays can be used as a tool for physicians to assess which patients might have the largest chance of benefitting from anti-PD-1/PD-L1 agents. However, because each inhibitor requires its own individual PD-L1 IHC assay, it is useful to have an upfront working knowledge of which targeted therapy is going to be used; otherwise the laboratory is required to run 5 different IHC tests, which raises costs and inefficiencies. There are several scenarios in which the FDA has mandated that PD-L1 positivity is required before anti-PD-1 agents are usable within approved indications. For example, patients with advanced, metastatic NSCLC can be treated in the front line with pembrolizumab monotherapy only if their PD-L1 tumor proportion score (TPS) is >50% (Table 2 .1). 127 In the second-line setting, pembrolizumab is FDA approved for adult patients with tumors (eg, gastric tumors) ( Table 2 . 3 42 ) that have a lower positive TPS score (>1%). 128 Interestingly, nivolumab has been approved as second-line therapy for select cancers regardless of their PD-L1 status. 129, 130 There is controversy over the use and reliability of PD-L1 IHC as a predictive biomarker. This is because of multiple factors:
• First, performing a PD-L1 IHC assay on a single tumor site at one time point does not take into account the intrapatient tumor heterogeneity that can exist and the variability in PD-L1 expression that can occur over time. 131 PD-L1 expression can be regulated by IFN-γ signaling from T-cell interactions and by several tumor-intrinsic pathways such as MAPK and PI3K/Akt signaling, as well as epigenetic factors.
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• A second issue is the range of antibody assays that have been developed 124 and the need for standardization.
There have been cross assay comparisons, particularly in NSCLC, for which the staining patterns were similar among the 28-8, 22C3, and SP142 antibodies. 133, 134 However, SP142 staining of tumor cell membranes was shown to be weaker, resulting in fewer positive tumor cells than some other assays. The 73-10 antibody was not included in these analyses.
• A final issue is related to PD-L1 IHC scoring: how does one define a PD-L1-positive from a PD-L1-negative tumor? PD-L1 staining of immune cells in the tumor microenvironment, such as macrophages, gives a signal that is erroneously included in tumor PD-L1 assessment. This is the case for 22C3 and SP142 assays. To date, no approaches or thresholds reach sufficient sensitivity or specificity to be predictive of a high likelihood of response to a given drug. Providers need to be familiar with the individual PD-L1 assays and scoring used for each agent and tumor type when making patient decisions based on PD-L1 results.
Microsatellite instability and deficient MMR
Microsatellites are lengths of DNA sequence that contain single nucleotide (mononucleotide) or sections of 2 or more nucleotide (dinucleotide, trinucleotide, tetranucleotide, or pentanucleotide) repeats (see Microsatellite instability-high tumors and DNA mismatch repair). When microsatellites contain a clonal change in several repeated DNA nucleotide units, this results in MSI (tumors with such MSI are characterized as MSI-H, and this occurs when at least one of the MMR genes-MSH2, MLH1, MSH6, and PMS2-are inactivated, causing dMMR). 10 Since MSI-H was established as a possible biomarker, the MSI status of a tumor has always required microdissection and PCR-based detection strategies. For practical purposes, MSI is equivalent to the loss of staining by IHC of at least one of the MMR genes because any lack of normal MMR protein expression signifies an abnormality in MMR and thus MSI. A sensitive and specific MSI assay by NGS has recently been developed that is comparable to the existing gold standard of PCR-based methods without requiring matched samples from tumor and normal tissues. 10 MSI appears to be a generalized cancer phenotype in about 4% of all adult cancers in total. MSI-H tumors are associated with an improved prognosis in early-stage cancers. In Table 3 140 and GI cancers. 141 There is ongoing discussion regarding the definition of "high" TMB for predictive purposes. Most studies report ≥17 mutations per MB as high TMB, which is based on comparing TMB with MSI in patients with CRC. This, of course, also shows that high TMB is in strong concordance with MSI-high in CRC. However, although TMB is associated with dMMR, not all tumors with a high TMB are actually associated with MSI-H, and future studies should address this aspect.
MSI and MMR, TMB, and PD-L1
The relationship between TMB, MSI, and PD-L1 has recently been explored in a broad range of cancer types (Fig. 1) . 10 There is some overlap of all 3 markers in a few cancers. However, in most cancers, overlap is infrequent or does not exist at all, and 69.5% of all cancer cases were negative for all 3 biomarkers (7890 of 11,348 tested). A population of tumors exhibiting MSI-H status but low TMB and no PD-L1 expression was identified. Since MSI/ MMR status alone or in combination with PD-L1 positivity became an accepted predictive marker in the FDA indication for checkpoint inhibitors, the finding that patients can test positively for only one of these markers obviously means that the number of patients now eligible to receive and hopefully benefit from checkpoint inhibition has been broadened. Until more is understood about how MSI, PD-L1, and TMB work together and how this interaction is clinically relevant, the only reasonable option is to continue to assay for all 3 markers and ensure that the number of patients who are given the chance to benefit from these drugs is maximized.
Polybromo 1
PBRM1 is a non-MSI/PD-L1/TMB marker that could be predictive for response to checkpoint inhibitors. For example, clear cell renal cell carcinoma (ccRCC) responds to immune therapy but, unlike many other responsive human tumors, harbors a low burden of somatic mutations. Even so, ccRCC has relatively high immune cytolytic activity and a microenvironment with high immune and T-cell infiltration scores. In the past, large-scale sequencing studies demonstrated that PBRM1 loss of function (LOF) alterations are present in a large portion (up to 41%) of ccRCC tumors. Patients whose tumors had PBRM1 loss in both gene copies had significantly prolonged OS and PFS and manifested reduced tumor burden in response to immune checkpoint therapy compared with patients without PBRM1 loss (log-rank P = .0074 and P = .029, respectively). Miao et al summarized that, given the high prevalence of PBRM1 LOF in ccRCC, this genetic mutation has important implications as a molecular tool for considering immune therapy responsiveness in ccRCC and possibly across other cancer types.
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The Role of HRD as an Emerging Biomarker
Repair of DNA double-strand breaks by cells is mediated by the HR pathway or nonhomologous end-joining. HR is a complex DNA repair pathway involving multiple steps and has been reviewed extensively. 143, 144 The BRCA1
and BRCA2 genes are critical for efficient double-strand DNA repair via HR and play an important role in the development and clinical progression of many cancers.
145,146 Apart from mutations in the BRCA1 and BRCA2 genes, there are several other mechanisms associated with HRD. Defects in HR repair can be because of epigenetic changes such as BRCA1 promoter methylation, somatic mutations in key HR-related genes, and frequent copy number alterations. 149 In addition, mutations in other genes may result in HR-defective tumors and include but are not limited to PALB2, RAD51, CHEK2, and ATM.
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The most common approach to test for HRD is genomic testing for alterations in BRCA1 and BRCA2 on the basis that BRCA1 and BRCA2 germline and somatic mutations are known to cause HRD. Testing for additional genes involved in DNA damage repair through HR can also be done through commercial resources. Several other approaches have been developed to measure tumor DNA repair function. 154 The myChoice HRD test is an NGS assay that uses DNA extracted from formalin-fixed, paraffin-embedded or frozen tumor tissue. A tumor can be characterized as HR-deficient or HR-nondeficient by combining the HRD score that it generates and its BRCA1/ BRCA2 mutation status. HRD is defined as an HRD score ≥42 or the presence of a mutation in BRCA1/BRCA2. As an example of its accuracy, the myChoice HRD assay was seen to identify 100% of BRCA-mutated tumors and 57% of non-BRCA-mutated tumors that had HR deficiencies in patients with platinum-sensitive, high-grade, serous or BRCA-mutated, recurrent ovarian cancer. 65 The FoundationFocus CDx BRCA (Foundation Medicine, Inc) assay was used to detect both germline and somatic BRCA1/BRCA2 mutation types associated with response to PARP inhibitor therapy. 155, 156 This modified NGS-based assay determined the percentage of genomic loss of heterozygosity, mutations in BRCA1/BRCA2, and other HR genes in tumor tissue of patients with ovarian cancers taking part in the ARIEL PARP inhibitor rucaparib trial. A prespecified cutoff of ≥14% for high loss of heterozygosity was determined. FoundationFocus CDx BRCA is the first FDA-approved companion diagnostic assay for rucaparib for the treatment of advanced ovarian cancer.
As we understand more about HRD in various cancer types, the indications for the use of PARP inhibitors will likely be broadened. Certain cancers, including ovarian, fallopian tube, breast, primary peritoneal, and GI (specifically 157, 158 Several PARP inhibitors have been FDA approved for the treatment of specific types of ovarian (olaparib, rucaparib, and niraparib), fallopian tube (olaparib and niraparib), breast (olaparib), primary peritoneal (olaparib and niraparib), and pancreatic (olaparib) cancers, but not yet for other GI cancers. However, at present, HRD testing before PARP-inhibitor therapy is not necessary.
Other Hot Markers in Research
Although it is not by any means an exhaustive list, some exciting new biomarkers and their targeted therapies are discussed below.
NTRK and Entrectinib
Entrectinib (RXDX-101) was granted a breakthrough therapy designation by the FDA in 2017 for use as a treatment for adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors who have either progressed after prior therapies or who have no acceptable standard therapy options (see also Neurotrophic receptor tyrosine kinase, above).
27,28 A trial studying the treatment of patients with solid tumors (breast cancer, cholangiocarcinoma, CRC, head and neck neoplasms, melanoma, neuroendocrine tumors, NSCLC, ovarian cancer, pancreatic cancer, papillary thyroid cancer, primary brain tumors, renal cell carcinoma, and sarcomas) that harbor an NTRK1/ NTRK2/NTRK3, ROS1, or ALK fusion is ongoing (Clini calTr ials.gov identifier NCT02568267). In this trial, patients are assigned to different baskets according to tumor type and gene fusion. The primary outcome of the study will be the objective response rate to entrectinib.
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NTRK fusions may act as actionable targets in conjunction with other potentially targetable alterations, such as PD-L1-positive or MSI-H status, meaning that therapeutic combinations (TRK inhibitors plus immune checkpoint inhibitors, for example) are a promising strategy. 159 
FGFR and Erdafitinib
The fibroblast growth factor receptor (FGFR) family comprises part of a tyrosine kinase signaling pathway that plays a role in oncogenesis through gene amplification, activating mutations, or translocation in several tumor types. Erdafitinib is an orally administered FGFR family tyrosine kinase inhibitor. Earlier this year, the FDA granted Breakthrough Therapy Designation for erdafitinib in the treatment of urothelial cancer, which is based on data from a multicenter phase 2 clinical trial focused on evaluating the efficacy and safety of erdafitinib in the treatment of adult patients with locally advanced or metastatic urothelial cancer harboring specific FGFR mutations. 160 The overall response rate was 42% in 59 patients for whom data were available. 160 Erdafitinib is also under investigation in the NCI-MATCH trial as a treatment for patients with tumors that have an FGFR mutation, fusion, or amplification (Table 7) . Also in the NCI-MATCH trial, 5 of 50 patients with an aberrant FGFR pathway had a partial response to AZD4547 (another FGFR tyrosine kinase inhibitor). 161 Two of these patient's tumors had point mutations in FGFR2/FGFR3, and 2 others had FGFR3 fusions, suggesting that these particular types of mutation have increased sensitivity to the drug, which warrants further study in this patient subtype.
MET Amplification and MET Exon 14 and Crizotinib
Aberrant activation of MET receptor tyrosine kinase signaling occurs in various cancer types as result of various MET alterations, including amplification and an exon 14 mutation.
Crizotinib is an ALK/ROS1/MET inhibitor that is already FDA approved in ALK-positive or ROS1-positive NSCLC but also has proven clinical activity in cases of MET exon 14 alterations and MET amplification. Preclinical studies have shown that inhibition of MET using crizotinib resulted in the inhibition of growth of cancer cells that possessed MET amplification both in vitro in cell lines and in vivo in preclinical models. 162 In an updated phase 1 analysis of crizotinib in patients with low, medium, and high levels of MET amplification in advanced NSCLC, patients with high MET amplification showed clinically meaningful antitumor activity with rapid and durable responses. Crizotinib was generally well tolerated 163 and is currently under study in the ASCO TAPUR trial for patients with tumors that have ALK, ROS1, or MET mutations and in the NCI-MATCH trial as a treatment for patients with tumors that have a MET amplification, MET exon 14 mutation, ALK translocation, or ROS1 translocation or inversion (Table 7) .
mTOR and Sapanisertib (TAK-228)
The mammalian target of rapamycin (mTOR) is a kinase encoded in humans by MTOR. mTOR exists as a core component in 2 distinct multiple-protein complexes, TORC1 and TORC2. These complexes regulate several different cellular processes, including cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and transcription. Sapanisertib (TAK-228) demonstrated a reasonable safety profile as well as promising preliminary antitumor activity in a range of tumor types with aberrant MTOR. 164 Tuberous sclerosis complex 1 and 2 (TSC1 and TSC2) mutations are also observed in certain tumor subtypes and may be targeted by sapanisertib.
The agent is under investigation in the NCI-MATCH trial as a treatment for patients with tumors that have MTOR or TSC1/TSC2 mutations (Table 7) .
PIK3CA and Taselisib
In the NCI-MATCH trial, 65 patients with a mutated phosphatidylinositol 3-kinase gene (PIK3CA) were treated with taselisib (a PIK3CA inhibitor) and, although there were no ORs to the drug, 24% of patients had prolonged stable disease for more than 6 months. Further research in selected cancer types is warranted.
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CDK4/CDK6 and Palbociclib
The cyclin-dependent kinases (CDKs) CDK4 and CDK6 play a crucial role in the G1-S phase transition during cell cycling. Palbociclib, an inhibitor of aberrant CDK4/ CDK6, is FDA approved for the treatment of hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women. 166 Its effect on certain GI tumors is under investigation in the clinic. 167 Palbociclib is also under investigation in the NCI-MATCH trial as a treatment for patients with tumors that have CDK4 or CDK6 amplification or CCND1, CCND2, or CCND3 amplification (and Rb expression/protein in both study arms). The ASCO TAPUR trial is also investigating palbociclib in the treatment of patients with tumors that harbor CDKN2A, CDK4, or CDK6 amplifications (Table 7) .
DDR2 and Dasatinib
DDR2 is a transmembrane receptor tyrosine kinase that plays a role in cancer progression by regulating the interactions of tumor cells with their surrounding collagen matrix. DDR2 mutations are seen in several tumor types, including lung cancer, breast cancer, brain cancer, gynecologic cancer, and prostate cancer. 168 The multikinase inhibitor dasatinib blocks DDR2 kinase activity to various degrees and is under investigation in the treatment of patients with tumors that possess a DDR2 S768R, I638F, or L239R mutation (NCI-MATCH). The agent is also under investigation in the treatment of patients with tumors that harbor Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, or YES1 mutations (TAPUR trial) ( Table 7) .
Emerging Techniques
The Liquid Biopsy: Circulating Tumor Cells and Exosomes
Peripheral blood samples are a biomarker source by way of circulating tumor cells (DNA) and circulating nucleic acids or associated extracellular vesicles or exosomes. [169] [170] [171] The use of liquid biopsy profiling has proven useful in selected clinical scenarios but, to date, despite its potential in the management of patients with most metastatic solid tumors, this technique has not established a firm role in standard practice. Obvious advantages include ease of access to the tissue through a simple blood draw. An additional advantage is that circulating samples may help reduce the problem of tumor heterogeneity as it reflects the sum total of the tumor. However, when blood and tumor tissue are concurrently collected and analyzed, results from circulating tumor cell analyses do not always match those obtained from tumor tissue analyses and thus are not always reliable.
Regarding extracellular vesicles or exosomes, a newly developed, minimally invasive ADAPT Biotargeting System characterizes complex biological systems in their inherent state(s) and relies on the fact that a large number of cells in the body secrete extracellular vesicles into the circulation, and the molecular composition of these "exosomes" correlates with the cell of origin. Through intercellular communication, exosomes play a part in controlling many tumor progressive processes, including immune evasion, angiogenesis, and metastasis. 171 The ADAPT assay has been shown to have potential for biomarker identification and therapeutic use across most cancer types.
171,172
Community Hospital Molecular Testing and Assessment Program
Because 85% of cancer care is delivered in a community setting, it is imperative that the programmatic decisions concerning molecular testing for cancer include standardization, physician engagement, and application to point of care. Hoag Hospital (a large community hospital in Newport Beach, California) decided to embark on an initiative within the context of precision oncology and identified the need for molecular testing. A committee of interested physicians (including molecular pathologists) and administrators was formed, and a request for proposal was developed and put to several CLIA-certified vendors to outsource genomic testing. Certain specific qualifications were emphasized, such as price point; turnaround time; results reporting and support structure; portfolio of testing, including NGS, CNV, and IHC for protein analysis and fusion genes (all preferably using disease-specific panels); and preauthorization and billing services. Several meetings were required to reach a final decision. Once the vendor was selected and contracting was optimized, all tumor molecular testing was standardized, and all ordering and tissue processing was sent through the central pathology laboratory. It is important to note that this process had immediate benefit for the cancer programs because, before this arrangement, molecular testing was haphazard. Tumor tissue samples were being sent by individual physicians to multiple different laboratories/ vendors without standardization of tissue collection and processing, and subsequent result reports were generally faxed and unavailable when needed for valuable treatment assessment in the standard clinical or research settings. After vetting and education concerning this new molecular testing and assessment program at disease site committee and tumor board meetings, it was further decided that genomic testing would be reflexed and ordered by pathology for selected clinical stages of solid tumors. The initial pilot project for this reflex testing was in NSCLC stages IB through IV. Before this initial pilot of genomic reflex testing in lung cancer, approximately 50% of the tumors in patients with advanced lung cancer were being tested for even the minimal NCCN guideline biomarkers. Now, over 95% of advanced lung cancers undergo genomic profiling evaluation that has resulted in pervasive use at the point of care. An illustrated example of this was a recent patient's lung cancer demonstrating an actionable mutation in BRAF. The success of this pilot study in reflex profiling has expanded to other cancer disease sites, such as advanced head and neck cancers, ovarian cancers, glioblastoma multiforme, sarcoma, and rare tumors. Over the past 18 months, more than 300 tumors have undergone clinical grade genomic profiling, and those data are readily available to the treating physician through web access. Importantly, physician education is a key component to the establishment of a comprehensive cancer molecular genomics program. Initiation of the more routine use of molecular markers and genomic profiling has stimulated interest and participation in the expanding clinical applications. Along with the assistance of molecular pathology, presentation of genomic data is now frequently requested, and this provides points of discussion in the cancer disease site tumor board meetings. In addition, this information has led to optimal patient selection and a definitive increase in referrals to the phase 1 clinical trials program.
Despite the successful implementation of this intuitional program in cancer molecular testing, challenges remain. These fall into several categories, such as reimbursement issues, evaluating the tumor genomic data for potential germline testing, paring results to clinical trial opportunities, and collecting and collating the genomic data to clinical information and outcomes, as well as the incorporation of new opportunities such as sequencing cell-free DNA or routine pharmacogenetic testing. The overall goal of this program was to provide added value and physician engagement in precision oncology. This is now a work in progress, but we are already evaluating the growth opportunity to enhanced patient care.
Challenges and Open Questions in Molecular Profiling
Absence of Randomized, Controlled Clinical Trials
One of the major challenges with the use of large panels or whole genome sequencing is the absence of randomized clinical trials demonstrating benefit. Although some retrospective analyses have appeared promising, in general, the field demands more evidence given the expense of drugs and genomic tests and potential harm from exposing patients to toxicity of drugs without proof of efficacy. A properly performed randomized clinical trial requires a large number of patients and needs to be a national study requiring significant resources to cover costs of testing, cost of drugs, and data analysis. It would be problematic to randomize patients to genomic profiling versus no testing. It is also complicated to compare standard therapy with molecularly assigned therapy in terms of comparing apples to apples and defining what the valid endpoints should be. It is clear that the gold standard is OS, but this may be affected by multiple lines of therapy and ultimate use of targeted therapy beyond a particular study. PFS is a reasonable endpoint but, if the randomization occurs at a time when there is effective standard therapy, then the impact of molecularly targeted therapy may be underestimated. With the era of precision oncology, there is opportunity to break new ground in trial design. In this regard, pooling N-of-one data that account for other factors described below, such as tumor heterogeneity, may allow for useful evidence to help patients even if it does not rise to randomization. In addition, the PFS ratio as defined by Von Hoff remains a good metric to determine benefit of molecularly assigned therapy.
Lack of Drugs
Another major challenge is the lack of availability of drugs for numerous drivers of various cancers. Examples of major drivers for which there are currently no approved drugs include mutated β-catenin, mutated P53, or mutated RAS, among others. On the optimistic side, as drugs are discovered and developed, they can be offered retrospectively to patients who have actionable mutations. A related issue is the lack of drugs that effectively target emergent resistance mechanisms. There are some exceptions with mutated EGFR, ALK, or BCR-ABL.
Tumor Heterogeneity
It is clear that advanced cancers, especially those that have been treated, harbor significant tumor heterogeneity. This includes intralesion heterogeneity, interlesion heterogeneity, and interpatient heterogeneity, all of which complicate treatment recommendations and outcomes of studies.
Platform Heterogeneity
In clinical practice, there are several different available platforms for molecular profiling; each test has its own sensitivity and specificity. The scope of the testing varies in the number of genes, whether RNA or protein expression is assessed, and whether actionable fusions are readily detectable. Such heterogeneity makes it difficult to pool data from different platforms. The various commercial platforms or those performed within academic institutions are continuously evolving, further complicating the issue of platform heterogeneity. Thus older platforms that did not capture actionable targets for which there are effective therapies lead to data sets that may underestimate the value of genomic testing with respect to patient outcomes. Moreover, no study to date has shown that larger panels are worth doing over smaller targeted gene panels that are part of standard of care (eg, KR AS, NR AS, BR AF, and MSI in CRC). However, it is not unreasonable to expect that the many genomic changes representing the tail end of the curve of drivers may affect patient outcomes, especially if there are available drugs that target their pathways. With the emergence and popularity of liquid biopsy, this yet further adds complexity to the platforms. Of note, in the TAPUR study, which models real-life situations, liquid biopsy is acceptable for the identification of actionable targets to allow enrollment in a treatment arm.
CLIA-approved laboratories offering molecular panel analysis
Before a patient sample of any kind can be tested, the assay in question must be validated in a CLIA-certified laboratory. CLIA defines a clinical laboratory as any facility that performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or impairment. The CMS regulates all laboratory testing performed on humans in the United States through the CLIA program. In total, CLIA covers approximately 260,000 laboratory entities. The Division of Clinical Laboratory Improvement and Quality, within the Quality, Safety, and Oversight Group under the Center for Clinical Standards and Quality, has responsibility for implementing the CLIA program. The objective of the CLIA program is to ensure quality laboratory testing. Although all clinical laboratories must be properly certified to receive Medicare or Medicaid payments, CLIA has no direct Medicare or Medicaid program responsibilities.
Clinical laboratories must constantly evolve their test offerings to support the most recent advances in cancer care. For NGS tumor profiling assays, there are multiple commercially available kits with similar claims for gene content and sensitivity. Many factors contribute to the decision of which assays or customized solutions will best meet the needs of the laboratory, clinicians, and patient population. Kit costs, capital equipment expenditures, complexity of workflow, and turnaround time are all important factors that can be relatively easily compared and assessed between assay systems. However, the more important parameters for determining effective, personalized treatment for patients are accuracy, reproducibility, and sensitivity of the assay, and these can be much more challenging to critically evaluate but must be rigorously validated. [173] [174] [175] [176] The use of a highly multiplexed, consistent, and well-characterized reference material greatly facilitates the comparison of assay systems. 177 
Data Sharing
Given the numerous challenges described above and others, including limitations of electronic medical records, issues with intellectual property, commercial interests, Health Insurance Portability and Accountability Act of 1996 (HIPAA) regulations, and quality of clinical outcomes data, there are major difficulties with data sharing to expand data sets through larger sample size. In this regard, the Caris Precision Oncology Alliance has been addressing some of the issues through the CODE database, which is increasing the number of patients for whom analysis of clinical outcomes is possible as a function of clinical, genomic, or drug use. Other initiatives of national prominence include Orion, Project GENIE, the WIN Consortium, the Precision Medicine Exchange Consortium, and the Memorial Sloan Kettering (MSK) Cancer Alliance.
Timing
The ideal time to perform genomic testing to maximize its therapeutic value to individual patients with cancer remains a matter of controversy, and the evidence base on which to make recommendations is still evolving. Initially, physicians mainly ordered testing in patients with advanced disease who had exhausted standard-of-care treatment options to help inform choices for treatment with experimental agents. Trials are now underway in groups of patients with earlier stages of disease. For example, the newly activated, NCI-sponsored intergroup stage III colon cancer adjuvant therapy trial randomizes patients to standard adjuvant therapy with FOLFOX or FOLFOX plus experimental treatment with a PD-1 inhibitor. Only patients with MSI-H, stage III colon cancer will be eligible for randomization, and the eligibility determination mandates genomic testing for defective MMR in patients with localized disease. Commercial genomic testing now includes MSI testing in addition to a battery of genes relevant to tumor progression. The addition of MSI testing to these panels is a consequence of the recent approval of pembrolizumab and nivolumab. The agents are currently approved for the treatment of refractory tumors of any histology that exhibit defective MMR. 141 In patients with advanced cancers, it is clear that the tumor genome continues to evolve with time and with the pressure exerted on cells by treatments that selectively favor the growth of treatment-resistant subclones. 178 Investigators remain concerned about clonal evolution and often will recommend rebiopsy of tumors when patients have refractory disease to ensure that the genomic analysis used to make informed decisions about clinical trials with targeted agents is ref lective of the tumor's current biology. 179 Others suggest testing at the first sign of advanced disease, as the efficacy of conventional chemotherapy is variable and strategies for salvage therapy may be required sooner rather than later. The use of "liquid biopsies" either on circulating tumor cells or on cell-free DNA has been touted as a method of assessing the tumor genome without the need for a repeat, invasive biopsy. This remains a research tool at this time and is not generally a part of clinical practice. Continued data analyses are urgently needed and will inevitably occur as more samples are tested and the practical application of these assessments are translated into treatment decisions.
Discussion
In 2019, optimum cancer care requires state-of-the-art molecular diagnostics, a solid knowledge base to interpret and apply the results, and a nearly constant awareness of changes on the horizon. The field is moving that quickly. Comprehensive testing performed on our patients at the beginning of 2019 is likely to be incomplete today. Drug approvals are no longer based solely on large phase 3 trials; these late-stage trials are being replaced by "basket" and "umbrella" trials, allowing us to ensure that the right drug is given to the right patient faster. Subsequent new regulatory and payer approvals seem to come daily. Precision medicine is now a part of our standard practice, but with this comes many new challenges. How do we deal with tumor heterogeneity, and will liquid biopsies satisfactorily replace tissue-based testing? Are we justified in, and can we afford, testing a large sample of patients, knowing that we will only rarely find the sought after "needle in the haystack?" How do we manage our patients' expectations when there is so much press and hype surrounding our new discoveries? Can we afford to develop and ultimately to pay for increasingly expensive therapies targeting increasingly smaller proportions of patients? There is, of course, no turning back, but there is much work ahead. ■ 
